Effects of Angiotensin II Type 1 Receptor Antagonist, YM358, on Cardiac Hypertrophy and Dysfunction after Myocardial Infarction in Rats
スポンサーリンク
概要
- 論文の詳細を見る
This study was undertaken to investigate the effects of an angiotensin II type 1 receptor antagonist, YM358 (2,7-diethyl-5-[[2'(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-5H-pyrazolo [1,5-b] [1,2,4]triazole potassium salt monohydrate), on cardiac hypertrophy and dysfunction in rats with heart failure after myocardial infarction (MI). One day after the coronary ligation, rats were randomized, and administered YM358 or vehicle for 2, 4 or 8 weeks. In MI rats, mean blood pressure, left ventricular (LV) systolic pressure, and the first derivative of LV pressure significantly decreased, and LV end-diastolic pressure (LVEDP) markedly increased after 2 to 8 week treatment of YM358. From 2 weeks after the ligation, ratios of cardiac weight and lung weight to body weight (BW) significantly increased, which indicated the progression of cardiac hypertrophy and lung congestion in MI rats. Two weeks after the ligation, YM358 did not improve LV function, although it decreased the elevated LVEDP and cardiac weights/BW ratios 8 weeks after the ligation. These results indicated that long-term treatment with YM358 improves the reduced cardiac function and reduces cardiac hypertrophy after MI, and may be useful for the treatment of congestive heart failure.
- 公益社団法人日本薬学会の論文
- 2002-07-01
著者
-
FUJIMORI Akira
Applied Pharmacology Research Laboratories, Drug Discovery Research, Astellas Pharma Inc.
-
Matsuda-satoh Yasuko
Institute For Drug Discovery Research Yamanouchi Pharmaceutical Co.
-
Fujimori Akira
アステラス製薬研究本部薬理研究所
-
Fujimori Akira
Applied Pharmacology Research Laboratories Drug Discovery Research Astellas Pharma Inc.
-
Yanagisawa I
Yamanouchi Pharmaceutical Co. Ltd. Ibaraki Jpn
-
Yanagisawa Isao
Institute For Drug Discovery Research Yamanouchi Pharmaceutical Co.
-
Yanagisawa Isao
山之内製薬
-
Shibasaki Masayuki
Institute For Drug Discovery Research Yamanouchi Pharmaceutical Co.
-
Shibasaki Masayuki
General Education Courses Faculty Of Engineering Toyo University
-
Inagaki Osamu
Institute For Drug Discovery Research Yamanouchi Pharmaceutical Co.
-
Fujimori Akira
Institute For Drug Discovery Research Yamanouchi Pharmaceutical Co.
-
TOKIOKA-AKAGI Tomoko
Biometrics Department, Yamanouchi Pharmaceutical Co., Ltd.
-
Tokioka-akagi Tomoko
Biometrics Department Yamanouchi Pharmaceutical Co. Ltd.
関連論文
- New Topics in Vasopressin Receptors and Approach to Novel Drugs : Research and Development of Conivaptan Hydrochloride (YM087), a Drug for the Treatment of Hyponatremia
- Synthesis and Structure-Activity Relationships in a Series of Ethenesulfonamide Derivatives, a Novel Class of Endothelin Receptor Antagonists
- Ethenesulfonamide Derivatives, a Novel Class of Orally Active Endothelin-A Receptor Antagonists
- Novel Potassium Channel Activators : Synthesis and Structure-Activity Relationship Studies of 3,4-Dihydro-2H-1,4-benzoxazine Derivatives
- An Easy Access to 7-Methyl-2-naphthalenecarbonitrile
- Studies on Nonpeptide Angiotensin II Receptor Antagonists. IV. Synthesis and Biological Evaluation of 4-Acrylamide-1H-imidazole Derivatives
- Studies on Nonpeptide Angiotensin II Receptor Antagonists. III. Synthesis and Biological Evaluation of 5-Alkylidene-3,5-dihydro-4H-imidazol-4-one-Derivatives
- Studies on Nonpeptide Angiotensin II Receptor Antagonists. II. Synthesis and Biological Evaluation of 5H-Pyrazolo[1,5-b][1,2,4]triazole Derivatives with a C-Linked Oxygen Functional Group at the 6-Position
- Studies no Nonpeptide Angiotensin II Receptor Antagonists. I. Synthesis and Biological Evaluation of Pyrazolo[1,5-b][1,2,4]triazole Derivatives with Alkyl Substituents
- Novel Potassium Chennel Activators. II. Synthesis and Pharmacological Evaluation of 3,4-Dihydro-2H-1,4-benzoxazine Derivatives : Modificaiton of the Aromatic Part
- Cardiovascular Effects of YM430,a 1,4-Dihydropyridine Derivative with β-Adrenoceptor Blocking Activity, in Dogs and Rats
- Synthesis and Biological Evaluation of Quinuclidine Derivatives Incorporating Phenothiazine Moieties as Squalene Synthase Inhibitors
- Comparison between YM099 and Captopril in Rats with Renal Mass Reduction-Induced Progressive Renal Disease(Pharmacology)
- Novel Potassium Channel Activators. III. Synthesis and Pharmacological Evaluation of 3,4-Dihydro-2H-1,4-benzoxazine Derivatives : Modification at the 2 Position
- Synthesis of Novel Succinamide Derivatives Having the 5,11-Dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one Skeleton as Potent and Selective M_2 Muscarinic Receptor Antagonists. I
- Novel 5-Hydroxytryptamine (5-HT_3) Receptor Antagonists. Synthesis and Structure-Activity Relationships of 9-Methyl-2,3,4,9-tetrahydrothiopyrano[2,3-b]indol-4-one Derivatives
- Novel 5-Hydroxytryptamine (5-HT_3) Receptor Antagonists. III. Pharmacological Evaluations and Molecular Modeling Studies of Optically Active 4,5,6,7-Tetrahydro-1H-benzimidazole Derivatives
- Novel 5-Hydroxytryptamine (5-HT_3) Receptor Antagonists. II. Synthesis and Structure-Activity Relationships of 4,5,6,7-Tetrahydro-1H-benzimidazole Derivatives
- Novel 5-Hydroxytryptamine (5-HT_3) Receptor Antagonists. I. Synthesis and Structure-Activity Relationships of Conformationally Restricted Fused Imidazole Derivatives
- Antisecretory and Antiulcer Effects of YM020, a New H^+, K^+-ATPase Inhibitor, in Rats and Dogs
- A Novel Vasopressin Dual V_/V_2 Receptor Antagonist, Conivaptan Hydrochloride, Improves Hyponatremia in Rats with Syndrome of Inappropriate Secretion of Antidiuretic Hormone (SIADH)(Pharmacology)
- Synthesis and Pharmacological Evaluation of 2-(3-Piperidyl)-1,2,3,4-tetrahydroisoquinoline Derivatives as Specific Bradycardic Agents
- Synthesis and Biological Evaluation of Phenylacetyl Derivatives Having Low Central Nervous System Permeability as Potent and Selective M_2 Muscarinic Receptor Antagonists
- Synthesis of Novel Succinamide Derivatives Having a 5,11-Dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one Skeleton as Potent and Selective M_2 Muscarinic Receptor Antagonists. II
- Effects of YM358,an Angiotensin II Type 1 (AT_1) Receptor Antagonist, and Enalapril on Blood Pressure and Vasoconstriction in Two Renal Hypertension Models
- In Vitro and in Vivo Vasodilatory Activity of barnidipine and Its Enantiomers
- Effects of Angiotensin II Type 1 Receptor Antagonist, YM358, on Cardiac Hypertrophy and Dysfunction after Myocardial Infarction in Rats
- Comparison of the Angiotensin II Type 1-Receptor Antagonist YM358 and the Angiotensin-Converting Enzyme Inhibitor Enalapril in Rats With Cardiac Volume Overload
- Nuclear Magnetic Resonance of ^7Li in Li_2B_4O_7 Single Crystal and Glass
- Nuclear Magnetic Resonance of ^7Li in LiBO_2 Crystal
- Antihypertensive Effect of YM730, A New Calcium Antagonist, in Stroke-prone Spontaneously Hypertensive Rats